MKGAF:OTO-Merck Kgaa (USD)

COMMON STOCK | Drug Manufacturers - Specialty & Generic | OTC Pink

Last Closing

USD 162.23

Change

+0.23 (+0.14)%

Market Cap

USD 13.92B

Volume

58.00

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Merck KGaA is a pharmaceutical and chemical company. It produces prescription drugs, over-the-counter products and specialty products for the electronics, printing, coatings, cosmetics, food, pharmaceutical and biotechnology industries.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-05-03 )

Largest Industry Peers for Drug Manufacturers - Specialty & Generic

Symbol Name Price(Change) Market Cap
MKKGY Merck KGaA ADR

-0.30 (-0.82%)

USD 79.59B
TKPHF Takeda Pharmaceutical Co. Ltd.

N/A

USD 41.30B
HLNCF Haleon plc

-0.02 (-0.50%)

USD 37.62B
TEVJF Teva Pharmaceutical Industries..

N/A

USD 18.32B
SGIOY Shionogi & Co Ltd ADR

-0.09 (-0.78%)

USD 13.81B
SGIOF Shionogi & Co. Ltd

N/A

USD 13.81B
ESALF Eisai Co. Ltd

N/A

USD 12.59B
ESAIY Eisai Co. Ltd.

-0.12 (-1.10%)

USD 12.54B
IPSEY Ipsen SA ADR

N/A

USD 10.63B
IPSEF Ipsen S.A

N/A

USD 10.63B

ETFs Containing MKGAF

KLDW Knowledge Leaders Develop.. 0.00 % 0.75 %

+0.04 (+0.09%)

USD 0.14B

Market Performance

  Market Performance vs. Industry/Classification (Drug Manufacturers - Specialty & Generic) Market Performance vs. Exchange (OTC Pink)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 0.76% 53% F 53% F
Dividend Return 1.48% 47% F 39% F
Total Return 2.24% 53% F 54% F
Trailing 12 Months  
Capital Gain -9.96% 64% D 52% F
Dividend Return 1.32% 15% F 16% F
Total Return -8.64% 63% D 51% F
Trailing 5 Years  
Capital Gain 52.47% 94% A 82% B
Dividend Return 9.25% 67% D+ 31% F
Total Return 61.72% 93% A 81% B-
Average Annual (5 Year Horizon)  
Capital Gain 14.36% 69% C- 61% D-
Dividend Return 15.52% 68% D+ 59% D-
Total Return 1.17% 24% F 32% F
Risk Return Profile  
Volatility (Standard Deviation) 29.68% 88% B+ 72% C
Risk Adjusted Return 52.31% 96% N/A 88% B+
Market Capitalization 13.92B 100% F 99% N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Dividend Growth

This stock has shown top quartile dividend growth in the previous 5 years compared to its sector

What to not like:
Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Below median total returns

The company has under performed its peers on annual average total returns in the past 5 years.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector